Intervention Protocol

You have free access to this content

Aripiprazole for neuroleptic induced hyperprolactinaemia

  1. Venkata B Kolli1,*,
  2. Durga P Bestha2,
  3. Vishal Madaan3,
  4. Seenaiah Byreddy4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 16 OCT 2013

DOI: 10.1002/14651858.CD010786

How to Cite

Kolli VB, Bestha DP, Madaan V, Byreddy S. Aripiprazole for neuroleptic induced hyperprolactinaemia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010786. DOI: 10.1002/14651858.CD010786.

Author Information

  1. 1

    Creighton-Nebraska Psychiatry Residency Programme, Psychiatry, Omaha, Nebraska, USA

  2. 2

    Carolinas HealthCare System, Behavioral Health Center, Charlotte, North Carolina, USA

  3. 3

    University of Virginia, Department of Psychiatry & Neurobehavioral Sciences, Virginia, USA

  4. 4

    University of Arizona, Neurology, Tuscon, Arizona, USA

*Venkata B Kolli, Psychiatry, Creighton-Nebraska Psychiatry Residency Programme, 985582 Nebraska Medical Centre, Omaha, Nebraska, 68198-5582, USA.

Publication History

  1. Publication Status: New
  2. Published Online: 16 OCT 2013



Additional references

Altman 1996
Belgamwar 2011
Bernichtein 2010
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
Burstein 2005
  • Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. Journal of Pharmacology and Experimental Therapeutics 2005;315(3):1278-87.
Byerly 2009
  • Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia Research 2009;107(2-3):218-22.
Cada 2003
  • Cada DJ, Levien T, Baker DE. Formulary drug review aripiprazole. Hospital Pharmacy 2003;38(3):247-56.
Casey 2004
Crumlish 2009
  • Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. British Journal of Psychiatry 2009;194(1):18-24.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town. Cape Town: The Cochrane Collaboration, 2000.
Demyttenaere 1998
DiBonaventura 2012
  • Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20. [DOI: 10.1186/1471-244X-12-20]
Divine 1992
Donner 2002
Egger 1997
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
GRADE Profiler [Computer program]
  • GRADE Working Group. GRADE Profiler. Version 3.2. GRADE Working Group, 2004.
Grattan 2008
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
Holt 2008
  • Holt RI. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. Journal of Psychopharmacology 2008;22:28–37.
Hutton 2009
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Knegtering 2004
  • Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, Van Den Bosch RJ. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology 2004;24(1):56-61.
Lawler 1999
  • Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27.
Leucht 2005
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
Leucht 2005a
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Leucht 2009
  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 Jan;373(9657):31-41.
Marken 1992
Markianos 2001
  • Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. European Archives of Psychiatry and Clinical Neuroscience 2001;251(3):141-6.
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
McGrath 2008
Meaney 2004
  • Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry 2004;184:503-8.
Mir 2008
  • Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. Journal of Psychopharmacology 2008 May;22(3):244-53.
Molitch 2005
Overall 1962
Perkins 2002
Peuskens 1998
  • Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: The unspoken side effect of antipsychotics. European Psychiatry 1998;13:23-30.
Review Manager (RevMan) [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rummel-Kluge 2010
  • Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2010 Nov;123(2-3):225-33.
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Shapiro 2003
  • Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003 Aug;28(8):1400-11.
Shim 2007
  • Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry 2007;164(9):1404-10.
Smith 2003
  • Smith S. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. Journal of Clinical Psychopharmacology 2003;23:S27–S32.
Spollen 2004
Staller 2006
Turkington 1972
  • Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Archives of Internal Medicine 1972;130(3):349-54.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: A systematic review. Health Technology Assessment 1999;3(5):1-75.
Wudarsky 1999
  • Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 1999;9(4):239-45.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.